Does WellCare Cover Forteo? A Woman's Guide to Teriparatide Insurance Coverage

What Is Forteo and Why Do Women Need It?

Forteo is a brand-name anabolic bone agent. Most osteoporosis drugs slow bone breakdown. Forteo does the opposite: it actively stimulates new bone formation by mimicking parathyroid hormone (PTH 1-34). That mechanism makes it one of only a handful of drugs that can rebuild bone density rather than just preserve what remains.

Women carry a disproportionate share of the osteoporosis burden. Approximately 80% of the 10 million Americans with osteoporosis are women, and the fracture risk escalates sharply in the years immediately following menopause because estrogen withdrawal accelerates bone resorption. The NOF/Bone Health and Osteoporosis Foundation estimates that a 50-year-old white woman has a lifetime fracture risk of roughly 50%, comparable to her combined risk of breast cancer, uterine cancer, and ovarian cancer combined.

Forteo is specifically indicated for:

• Postmenopausal women with osteoporosis at high or very high fracture risk
• Women who have had a fragility fracture
• Women with a T-score at or below -2.5 with additional risk factors
• Women who have failed or cannot tolerate antiresorptive therapy (bisphosphonates, denosumab)

How Forteo Works in a Woman's Body

Teriparatide is a 34-amino-acid recombinant peptide administered daily as a subcutaneous injection. In the FRACTURE Prevention Trial (FPT), 1,637 postmenopausal women with prior vertebral fractures who received teriparatide 20 mcg/day for a median of 21 months showed a 65% relative risk reduction in new vertebral fractures and a 53% relative risk reduction in nonvertebral fractures compared with placebo.

Sex-specific pharmacokinetics matter here. Women on average have lower body weight than men included in early trials, and bioavailability after subcutaneous injection shows moderate variability. The approved dose of 20 mcg/day is the same regardless of body weight or menopausal status, but your bone turnover markers (P1NP, CTX) may respond differently depending on whether you are premenopausal, perimenopausal, or postmenopausal at the time of treatment.

Life Stage Matters for Who Gets Prescribed Forteo

Postmenopausal women are the primary population. Estrogen deficiency creates a high-turnover state where Forteo's anabolic signal is particularly effective.

Perimenopausal women rarely meet criteria unless they have secondary causes of bone loss (glucocorticoid use, malabsorption, premature ovarian insufficiency).

Premenopausal women represent a small but real patient group. Guidelines from ACOG note that premenopausal osteoporosis requires careful workup for secondary causes before starting anabolic therapy.

Women with premature ovarian insufficiency (POI) before age 40 face accelerated bone loss and may need aggressive treatment earlier than typical postmenopausal women.

Does WellCare Actually Cover Forteo?

The short answer is yes, but with significant conditions attached.

WellCare offers Medicare Advantage (Part D drug coverage), Medicaid managed care, and marketplace plans across multiple states. Forteo's coverage status depends on which specific WellCare plan you hold, your state's Medicaid rules if applicable, and whether you meet clinical criteria for prior authorization.

WellCare Medicare Advantage / Part D Plans

On most WellCare Medicare Advantage Part D formularies, Forteo appears as a Tier 4 or Tier 5 specialty drug. This tier placement means your cost-sharing before reaching catastrophic coverage can be substantial: copays in the $150 to $500 per 28-day supply range are not unusual in the initial coverage phase, though the Inflation Reduction Act's $2,000 out-of-pocket cap for Medicare Part D that took effect in 2025 offers meaningful relief.

You must confirm your specific plan's formulary at medicare.gov's Plan Finder or call WellCare directly, because formularies change annually and Forteo's tier can shift from one plan year to the next.

WellCare Medicaid Plans

Medicaid coverage of Forteo varies by state. Some state Medicaid programs carve out specialty injectables, while others cover them under the pharmacy benefit with prior authorization. WellCare administers Medicaid managed care in states including Florida, Georgia, Kentucky, Missouri, Nebraska, and others. In states where WellCare manages the pharmacy benefit, Forteo is generally covered when clinical criteria are met, but state Medicaid preferred drug lists often mandate bisphosphonate or denosumab failure first.

Prior Authorization: What Your Doctor Must Prove

Almost every WellCare plan requires prior authorization (PA) for Forteo. The PA criteria typically require your clinician to document:

1. A DXA scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, OR a history of low-trauma fracture
2. Failure of or contraindication to at least one antiresorptive agent (usually a bisphosphonate such as alendronate or risedronate taken for a minimum of 6 to 12 months)
3. A diagnosis consistent with high or very high fracture risk using a validated tool such as FRAX
4. Confirmation that serum calcium and vitamin D have been assessed
5. A statement that Forteo will not be used beyond 2 years (FDA-mandated lifetime limit)

The table below summarizes the typical PA documentation checklist your clinician will need to submit:

| Requirement | Typical WellCare Standard | |---|---| | DXA T-score | At or below -2.5, or fragility fracture documented | | Step therapy | Prior bisphosphonate trial (6-12 months) or documented contraindication | | Prescriber type | MD, DO, NP, or PA; some plans require endocrinologist or rheumatologist | | Lab values | Serum calcium, 25-OH vitamin D within 12 months | | Duration approved | 12 months, renewable once (total 2-year max) | | Renewal documentation | Follow-up DXA or bone turnover markers (P1NP) showing response |

Step Therapy: The Drugs You May Have to Try First

WellCare step therapy for osteoporosis almost always starts with bisphosphonates, the first-line standard under guidelines from The Menopause Society and ACOG.

Bisphosphonates as Step One

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly or 150 mg monthly) are generic and inexpensive. If you genuinely cannot tolerate them due to upper GI symptoms, esophageal disease, or kidney impairment (eGFR <35 mL/min/1.73m² for most oral bisphosphonates), your doctor should document that contraindication explicitly in the PA request. GI intolerance must typically be documented with a prescriber's attestation, not just patient report.

Denosumab as a Potential Step Two

Some WellCare plans require a trial of denosumab (Prolia) before approving Forteo, particularly if you are already a WellCare Medicare member. Denosumab is a RANK-L inhibitor given as a 60 mg subcutaneous injection every 6 months. The FREEDOM trial showed it reduced vertebral fracture risk by 68% and hip fracture risk by 40% over 36 months in postmenopausal women. Denosumab is generally Tier 3 on WellCare formularies and may have lower cost-sharing than Forteo.

When Step Therapy Can Be Bypassed

WellCare plans subject to state or federal step therapy override laws must grant an exception if:

• The required step therapy drug is contraindicated
• You already tried and failed the required agent
• The delay required to complete step therapy would cause serious harm
• A different drug is clinically superior for your specific condition

Your clinician can submit a step therapy exception simultaneously with the initial PA request if you already have documented failure or contraindication.

Forteo Alternatives on WellCare Formularies

If Forteo is denied or cost-prohibitive, several alternatives exist.

Tymlos (Abaloparatide)

Tymlos (abaloparatide 80 mcg/day subcutaneous injection) is the other FDA-approved daily anabolic agent and is often on a similar or slightly lower formulary tier than Forteo on WellCare plans. The ACTIVE trial showed a 43% relative risk reduction in new vertebral fractures versus placebo over 18 months in postmenopausal women. Some WellCare formularies actually prefer Tymlos over Forteo as the anabolic of choice.

Biosimilars: Bonsity and Tymlos

Bonsity (teriparatide-tjwp) is an FDA-approved teriparatide biosimilar that may carry a lower list price than brand Forteo and may be placed on a more favorable tier on some WellCare plans. Ask your pharmacist to run a formulary check specifically for Bonsity in addition to Forteo.

Evenity (Romosozumab)

Romosozumab (Evenity 210 mg monthly subcutaneous injection for 12 months) is a sclerostin inhibitor with a dual mechanism: it increases bone formation and decreases bone resorption simultaneously. The FRAME trial demonstrated a 73% reduction in new vertebral fractures at 12 months in postmenopausal women. Evenity carries an FDA boxed warning for cardiovascular risk (myocardial infarction and stroke), so it is generally avoided if you have had a prior cardiac event. On WellCare formularies, Evenity is typically also a Tier 4 or 5 specialty drug requiring PA.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Forteo is contraindicated in pregnancy. This is not a soft warning.

Animal studies showed that teriparatide increased the incidence of fetal skeletal abnormalities and neonatal hypercalcemia at doses approximating the human dose. FDA labeling for teriparatide assigns it to a category that means: "Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans." The drug should be discontinued immediately if you become pregnant.

Lactation

There are no published data on whether teriparatide passes into human breast milk. Given the lack of safety data and the non-urgent nature of osteoporosis treatment in most lactating women, Forteo is not recommended during breastfeeding. The decision to discontinue breastfeeding or discontinue the drug should take into account the severity of your bone disease. For most postpartum women, deferring Forteo until after weaning is the appropriate clinical approach.

Contraception Requirements for Women of Reproductive Age

Premenopausal women prescribed Forteo should use reliable contraception throughout treatment. This applies to women with:

• Glucocorticoid-induced osteoporosis
• POI-related bone loss being treated off-label
• Premenopausal osteoporosis from secondary causes

The 2-year FDA lifetime limit on Forteo also means timing matters if you are planning a future pregnancy: coordinate with your clinician about sequencing bone-building therapy and family planning.

Postpartum Bone Loss: A Specific Situation

Postpartum and lactation-associated osteoporosis (PLO) is rare but real, estimated to affect between 1 in 43,000 pregnancies based on case series. Women who develop PLO typically present with severe vertebral fractures in the third trimester or early postpartum period. Case series and small retrospective data support the use of teriparatide in PLO after weaning, with significant bone density gains reported at 6 to 18 months. Insurance coverage for PLO may require additional documentation given the off-label nature of the indication in premenopausal/postpartum women.

Women's Conditions That May Affect Your Forteo Eligibility

PCOS and Bone Health

Women with polycystic ovary syndrome (PCOS) have a complex bone profile. The hyperandrogenic environment may partially protect bone, but PCOS-associated menstrual irregularity and hypoestrogenism in some phenotypes can contribute to bone loss. Coverage criteria for Forteo do not specifically address PCOS, but a PCOS patient who has developed secondary amenorrhea-related osteoporosis should meet the same T-score and fracture-risk thresholds as any other woman.

Premature Ovarian Insufficiency

POI before age 40 causes accelerated bone loss equivalent to or worse than natural menopause. ACOG Practice Bulletin 234 recommends hormone therapy as the first intervention for bone protection in POI, not bisphosphonates. Forteo is rarely first-line here; however, women with POI who have already sustained significant bone loss despite adequate HRT may eventually become candidates.

Glucocorticoid-Induced Osteoporosis

Women with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) often use systemic glucocorticoids long-term. The 2022 ACR guidelines for glucocorticoid-induced osteoporosis recommend teriparatide over bisphosphonates for very high-risk patients on prednisone-equivalent doses at or above 7.5 mg/day for more than 3 months, when fracture risk is very high. WellCare PA criteria may need to reference this specific guideline when the indication is glucocorticoid-induced rather than postmenopausal osteoporosis.

Endometriosis and GnRH Agonist Use

Women who have used GnRH agonists (leuprolide, nafarelin) for endometriosis or fibroids long-term face estrogen-deficiency bone loss that can, in severe cases, reach osteoporotic thresholds. These women are typically younger and premenopausal. Forteo coverage in this group requires careful documentation of both the cause of bone loss and the severity of the T-score.

How to Appeal a WellCare Denial

If WellCare denies your Forteo PA, you have rights under federal Medicare and Medicaid law.

Step 1: Standard Appeal (Redetermination)

File a written appeal within 60 days of the denial notice for Medicare Part D plans. WellCare must issue a decision within 7 calendar days for a standard appeal or 72 hours for an expedited appeal if your clinician certifies that waiting the standard timeframe would seriously jeopardize your health.

Step 2: Reconsideration by an Independent Review Entity

If WellCare upholds its denial, your case automatically moves to an independent review entity (IRE) contracted by CMS. The IRE conducts a fresh review. CMS data shows that enrollees who appeal Part D denials have their coverage approved in a meaningful proportion of cases, particularly when the prescribing clinician submits detailed clinical documentation.

Step 3: Administrative Law Judge Hearing

If the IRE denies coverage and the amount in controversy meets the threshold (approximately $180 in 2025), you may request a hearing before an Administrative Law Judge. This step is time-consuming but can be worth it for a medication with a $6,000 monthly list price.

What Your Doctor's Letter Must Include

Instruct your clinician to address each PA criterion individually in the appeal letter:

• Cite the specific T-score from the DXA report (date, machine, facility)
• List each bisphosphonate or antiresorptive agent tried, with start/stop dates and reason for discontinuation
• Quote the relevant guideline (for example, The Menopause Society or ACR) supporting the indication
• Describe the patient's fracture history with imaging documentation if available
• State explicitly that the 2-year FDA lifetime limit will be observed

Who This Treatment Is Right For and Who Should Pause

Good Candidates for Forteo (Supported by WellCare Criteria)

• Postmenopausal women with a T-score at or below -2.5 and one or more fragility fractures
• Women with very high FRAX scores despite bisphosphonate therapy
• Women who cannot tolerate oral bisphosphonates due to esophageal disease or renal insufficiency
• Women with glucocorticoid-induced osteoporosis at very high fracture risk
• Women who have lost bone density while on antiresorptive therapy

Women Who Should Not Use Forteo

• Pregnant women (contraindicated)
• Women with Paget's disease of bone
• Women with unexplained elevated alkaline phosphatase
• Women with prior skeletal radiation therapy (increased osteosarcoma theoretical risk per FDA boxed warning, based on rat carcinogenicity data at very high doses; no osteosarcoma excess has been observed in 15-year postmarketing surveillance)
• Women with hypercalcemia or primary hyperparathyroidism
• Women with bone metastases or prior malignancy involving bone

The Perimenopausal Gray Zone

If you are in perimenopause and your DXA shows osteopenia rather than osteoporosis (T-score between -1.0 and -2.5), Forteo is not indicated, and WellCare will not cover it at that threshold. The correct intervention at that stage is addressing modifiable risk factors, ensuring calcium (1,200 mg/day from food and supplements combined) and vitamin D (1,500 to 2,000 IU/day) adequacy, and discussing hormone therapy if you have menopausal symptoms, which itself has bone-protective effects as documented in the WHI hormone therapy trials.

Manufacturer Patient Assistance and Copay Programs

If WellCare approves Forteo but your cost-sharing remains unaffordable, Eli Lilly (the manufacturer) operates a patient assistance program. Note that manufacturer copay cards generally cannot be used by Medicare beneficiaries under federal anti-kickback rules, but Lilly's Lilly Cares Foundation program may provide medication at no cost for patients meeting income criteria.

For Medicaid members, the copay assistance issue does not arise in the same way because cost-sharing is typically minimal by law.

Ask your clinician's office to connect you with their specialty pharmacy liaison, who can often run a benefits investigation and identify assistance programs in a single call.

Monitoring While on Forteo: What WellCare May Require for Renewal

WellCare PA approvals for Forteo are typically granted for 12 months and require renewal documentation. At renewal, your plan will typically ask for:

• A repeat DXA scan or bone turnover markers showing a treatment response (rising bone mineral density or rising P1NP)
• Confirmation that you remain within the 2-year lifetime maximum
• Documentation that serum calcium remains within normal limits (Forteo can cause transient hypercalcemia)

The bone turnover marker P1NP (procollagen type I N-terminal propeptide) typically rises within 1 to 3 months of starting Forteo. A P1NP increase of 10 mcg/L above baseline is considered a positive monitoring response and can strengthen your renewal PA request. Ask your clinician to check P1NP at 3 months; it is inexpensive and tells you whether the drug is working before you wait for a full DXA cycle.

Transitioning Off Forteo: The Sequential Therapy Requirement

One fact that surprises many women: stopping Forteo without transitioning to an antiresorptive agent causes rapid bone loss. Bone mineral density gains made during Forteo treatment are largely lost within 12 to 18 months of stopping if you do not follow immediately with a bisphosphonate or denosumab. The Menopause Society specifically recommends sequential antiresorptive therapy after anabolic treatment.

WellCare will cover the follow-on bisphosphonate or denosumab as a separate prescription. Build this transition plan into your original conversation with your prescribing clinician before you start Forteo, not after you finish it.

The recommended sequence in most postmenopausal women is:

1. Forteo for up to 24 months
2. Immediate transition (within 30 days of last Forteo dose) to zoledronic acid 5 mg IV once yearly or alendronate 70 mg weekly
3. Reassess with DXA at 1 to 2 years post-transition

Your WellCare plan covers zoledronic acid under Part B (physician-administered infusion) rather than Part D pharmacy, which means different cost-sharing rules apply. Confirm with WellCare's member services whether your Medicare Advantage plan covers the infusion under the medical benefit before scheduling.